-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
R&D base
28
2025-02
Beijing Nuokanda Pharmaceutical Technology Co., Ltd. is an innovation-driven, full-chain pharmaceutical CRO enterprise specializing in formulation technology platforms tailored to clinical needs. It is recognized as a National High-Tech Enterprise, a National Intellectual Property Demonstration Enterprise, and hosts a Postdoctoral Research Station. For six consecutive years, the company has been ranked among the top 20 "China's Top 20 Pharmaceutical R&D Companies" by the All-China Federation of Industry and Commerce, and it has undertaken or participated in two key national major new drug development projects under the 13th Five-Year Plan. In 2023, Keyuan Pharmaceutical acquired a 12% stake in Nuokanda, making it the company's second-largest shareholder. Today, Nuokanda has become Keyuan Pharmaceutical's Beijing-based R&D hub.
2025-02-28
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline